Myanmar vs South Sudan: Prevalence rate of obesity in adults
Myanmar
8.1%
in 2024
South Sudan
8.9%
in 2024
Myanmar rank
182nd
South Sudan rank
179th
Prevalence rate of obesity in adults over time
- Myanmar
- South Sudan
How they compare
South Sudan currently reports 8.9% against 8.1% in Myanmar, a difference of 0.8%.
That makes South Sudan's figure about 1.1 times Myanmar's.
The two have swapped places 2 times across 45 shared years of data; in 1980 it was South Sudan ahead.
Myanmar ranks 182nd and South Sudan ranks 179th of 199 countries.
Across the 5 decades both report, Myanmar averaged higher in 3 and South Sudan in 2.
Head to head by decade
| Decade | Myanmar | South Sudan | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 1.5% | 1.5% | 0.0% | Myanmar |
| 1990s | 2.4% | 2.3% | 0.2% | Myanmar |
| 2000s | 3.9% | 3.8% | 0.1% | Myanmar |
| 2010s | 5.8% | 6.0% | 0.2% | South Sudan |
| 2020s | 7.6% | 8.2% | 0.6% | South Sudan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of obesity in adults, Myanmar or South Sudan?
- South Sudan, at 8.9% against 8.1% in Myanmar as of 2024.
- What is the difference in prevalence rate of obesity in adults between Myanmar and South Sudan?
- 0.8%, with South Sudan ahead.
- How many years of comparable data are there for Myanmar and South Sudan?
- 45 years are reported by both, from 1980 to 2024.
- How do Myanmar and South Sudan rank globally for prevalence rate of obesity in adults?
- Myanmar ranks 182nd and South Sudan ranks 179th of 199 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) β with minor processing by Our World in Data, published as Prevalence rate of obesity in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated prevalence of obesity in adults, based on general population surveys and statistical modeling. Obesity is a risk factor for chronic complications, including cardiovascular disease, and premature death.